Ipsen
France · FR0010259150 · reports in EUR · Europe
The answers
From the annual report for the year to Dec 31, 2024. Each line says what it is based on.
- Is it growing?Fair
- Revenue +8.1% in the year to Dec 31, 2024, on the year before.
- Is it a good business?Fair
- It earned 8.3% on its shareholders' equity in the year to Dec 31, 2024.
- Is it safe?Good
- Equity is 65% of its assets, and operations brought in cash in the year.
- Is the price fair?n/a
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2024, consolidated, in EUR.
€3.6B
revenue
14%
operating margin
€346M
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|
| Revenue | €2.7B | €3.2B | €3.3B | €3.6B |
| Operating profit | €825M | €730M | €816M | €497M |
| Net profit to shareholders | €647M | €649M | €644M | €346M |
| Earnings per share | €7.82 | €7.87 | €7.79 | €4.18 |
| Dividend per share | n/a | €1.20 | n/a | €1.20 |
| Cash from operations | €893M | €971M | €866M | €916M |
| Cash | €815M | €1.2B | €528M | €678M |
| Total assets | €5.0B | €5.6B | €6.3B | €6.4B |
| Equity | €2.7B | €3.3B | €3.8B | €4.2B |
What they do
In the company's own words, from the annual report.
Ipsen est un groupe biopharmaceutique mondial focalisé sur l’innovation et la Médecine de Spécialité
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.